Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.72 |
| ▸ | HPGD | P15428 | 1/20 | 0.72 |
| ▸ | LMNA | P02545 | 3/20 | 0.60 |
| ▸ | THRB | P10828 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 9/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2675351 | 0.85 | KDM4E (1.00) | KDM4EALDH1A1HPGDLMNATP53 | |
| SCHEMBL9144644 | 0.80 | THRB (0.54) | KDM4EALDH1A1HPGDLMNATHRB | |
| SCHEMBL5759739 | 0.75 | NOTUM (0.52) | KDM4EALDH1A1HPGDKMT2ANOTUM | |
| SCHEMBL2676912 | 0.75 | KDM4E (0.65) | KDM4EALDH1A1HPGDLMNATP53 | |
| SCHEMBL7828039 | 0.75 | KDM4E (1.00) | KDM4EALDH1A1HPGDLMNATP53 | |
| SCHEMBL679402 | 0.73 | KDM4E (0.57) | KDM4EALDH1A1HPGDLMNAKMT2A | |
| SCHEMBL1717554 | 0.72 | NOTUM (0.52) | KDM4EALDH1A1HPGDLMNATP53 | |
| Hydrochloric Acid SCHEMBL9146843 | 0.71 | TP53 (0.46) | KDM4EALDH1A1HPGDLMNATHRB | |
| SCHEMBL28580373 | 0.71 | PMM2 (0.49) | KDM4EALDH1A1HPGDLMNAKMT2A | |
| SCHEMBL926245 | 0.71 | BRD4 (0.74) | KDM4EALDH1A1HPGDLMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8173639-B2 | Isoquinolinone derivatives as NK3 antagonists | H. LUNDBECK A/S (DK) | 2012-05-08 | — | — | US | disclosed |
| EP-2150534-A1 | ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS | H. Lundbeck A/S (DK) | 2010-02-10 | — | — | EP | disclosed |
| US-20090143402-A1 | ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS | H. LUNDBECK A/S (DK) | 2009-06-04 | — | — | US | disclosed |
| WO-2008131779-A1 | ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS | H. LUNDBECK A/S (DK) | 2008-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143402-A1 | ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS | KCNQ3, KCNK3, GRIK3 | KDM4E 3176/4885ALDH1A1 2304/4885HPGD 1046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.